Chris Shibutani
Stock Analyst at Goldman Sachs
(2.73)
# 2,084
Out of 5,044 analysts
96
Total ratings
54%
Success rate
4.09%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PCVX Vaxcyte | Maintains: Buy | $138 → $100 | $44.57 | +124.37% | 2 | Apr 1, 2025 | |
| ERAS Erasca | Maintains: Buy | $3.5 → $3 | $2.44 | +22.95% | 7 | Mar 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Sell | $20 → $15 | $17.16 | -12.59% | 4 | Mar 14, 2025 | |
| ALKS Alkermes | Maintains: Buy | $30 → $32 | $31.00 | +3.23% | 7 | Feb 14, 2025 | |
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $105.03 | +30.44% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $13.51 | +144.26% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $415.34 | -27.29% | 4 | Nov 1, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $36.41 | +40.07% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $186.93 | -17.08% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $14.32 | -72.07% | 8 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $6.66 | +200.30% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $820.10 | -11.84% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $21.77 | +19.43% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $147.38 | +3.81% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $227.54 | -23.97% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $60.92 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $42.82 | +61.14% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $17.69 | -26.51% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $58.17 | -60.46% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $7.38 | +577.51% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $61.95 | -16.06% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $24.50 | +144.90% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $7.37 | +144.23% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $7.79 | +118.23% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.79 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.11 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.25 | - | 4 | Jan 24, 2018 |
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $138 → $100
Current: $44.57
Upside: +124.37%
Erasca
Mar 21, 2025
Maintains: Buy
Price Target: $3.5 → $3
Current: $2.44
Upside: +22.95%
Seres Therapeutics
Mar 14, 2025
Maintains: Sell
Price Target: $20 → $15
Current: $17.16
Upside: -12.59%
Alkermes
Feb 14, 2025
Maintains: Buy
Price Target: $30 → $32
Current: $31.00
Upside: +3.23%
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $105.03
Upside: +30.44%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $13.51
Upside: +144.26%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $415.34
Upside: -27.29%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $36.41
Upside: +40.07%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $186.93
Upside: -17.08%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $14.32
Upside: -72.07%
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $6.66
Upside: +200.30%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $820.10
Upside: -11.84%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $21.77
Upside: +19.43%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $147.38
Upside: +3.81%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $227.54
Upside: -23.97%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $60.92
Upside: -
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $42.82
Upside: +61.14%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $17.69
Upside: -26.51%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $58.17
Upside: -60.46%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $7.38
Upside: +577.51%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $61.95
Upside: -16.06%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $24.50
Upside: +144.90%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $7.37
Upside: +144.23%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $7.79
Upside: +118.23%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.79
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.11
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $5.25
Upside: -